

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV302399080US, in an envelope addressed to: MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 14, 2004

Signature: _____

(Mary Jane DiPalma)

Docket No.: ASZD-P02-029
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bondjers et al.

Application No.: Not Yet Assigned

Confirmation No.:

Filed: April 14, 2004

Art Unit: Not Yet Assigned

For: COMBINATION OF A BETABLOCKER
AND A CHOLESTEROL-LOWERING
AGENT

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application number 10/220790, filed September 4, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P02-029. A duplicate copy of this paper is enclosed.

Dated: April 14, 2004

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	Not Yet Assigned	
			Filing Date	April 14, 2004	
			First Named Inventor	Göran Bondjers	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	ASZD-P02-029

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,260,440	11-09-1993	Hirai et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-9802357-A1	01-22-1998	Astra Aktiebolag		
	BB	WO-9911260-A1	03-11-1999	Pfizer Inc.		
	BC	WO-9738694-A1	10-23-1997	Merck & Co., Inc.		
	BD	WO-0038725-A1	07-06-2000	G.D. Searle & Co.		
	BE	WO-0197751-A2	12-27-2001	AstraZeneca AB		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Eagles, C.J., et al. The effects of combined treatment with beta1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects". Br. J. Clin. Pharmacol. 43(3) 291-300 (1997).	
	CB	Foss, O., et al. Treatment of hypertensive and hypercholesterolaemic patients in general practice. Scand J Print Health Care, 17, 122-127 (1999).	
	CC	Pool, J., et al. Lovastatin and Coadministered Antihypertensive/Cardiovascular Agents. Hypertension, 19(3), 242-248 (1992).	
	CD	Witchitz, S., et al. Effets comparés du captopril et de l'aténolol sur le métabolisme lipidique chez des patients hypertendus hypercholestérolémiques traités par pravastatine. Presse Med, 25(40), 2013-2016 (1996).	
	CE	Garnett, W. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm, Vol. 52, 1639-1645 (1995).	
	CF	Berglund, G., et al. W:3 Imaging of Atherosclerosis: Low dose metoprolol and fluvastatin slow progression of atherosclerosis: Main results from BCAPS. XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000, 151(1), 4 (2000).	
	CG	Hedblad, B., et al. W:3 Imaging of Atherosclerosis: Low dose metoprolol and fluvastatin in silent atherosclerotic disease: Metabolic and adverse effects in BCAPS. XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000, 151(1), 24 (2000).	
	CH	Westergren, G., et al. Effective Once-Daily Treatment of Hypertension with Low-Dose, Controlled Release Metoprolol, Pooled Results from Three Randomized, Double-Blind, Placebo-Controlled Studies. Current Therapeutic Research 55(2), 142-148 (1994).	
	CI	Kaplan, J.R., et al. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. European Heart Journal, 8, 928-944 (1987).	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	April 14, 2004
				First Named Inventor	Göran Bondjers
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	ASZD-P02-029

	CJ	Ostlund-Lindqvist, A. Effect of Metoprolol on Diet-Induced Atherosclerosis in Rabbits. Arteriosclerosis, 8(1), 40-45 (1988).	
	CK	Ablad, B., et al. The role of sympathetic activity in atherogenesis: Effects of beta-blockade. American Heart Journal, 116, 322-327 (1988).	
	CL	Sanderson, J., et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br. Heart J, 74, 502-507 (1995).	
	CM	Oestlund-Lindqvist et al., "Effect of metoprolol on plasm lipids and arterial intimal lipid deposition in spontaneously hypertensive rats," Atherosclerosis (Shannon Ireland) 80(2):135-142 (1989)	
	CN	Dorland's Illustrated Medical Dictionary, 28th Edition, page 795 (1994)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--